Philip Morris International (PMI) has concluded its controversial £1.1bn takeover of UK health firm Vectura, becoming its majority shareholder, along with that of the Danish oral-products manufacturer Fertin Pharma.
Confirming the completion of the deal today, Vectura, which develops and manufactures inhalers, said that the offer from the Big Tobacco company –£1.65 per share – now becomes “unconditional in all respects”, meaning the remaining stakeholders cannot prevent it.
By signing up you agree to our Terms and Conditions Please note trial access may take up to 24 hours to be granted as access must be qualified by a member of the TobaccoIntelligence team.
